Industry

DUBLIN–(BUSINESS WIRE)–The “Global Pain Management Devices Market 2021-2031 by Product, Application, Mode of Purchase, and Region: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering. The global pain management devices market will reach $9,971.6 million by 2031, growing by 8.3% annually over 2021-2031, driven by the growing demand for chronic pain management … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Mini Bioreactors and Micro Bioreactors Market, Distribution by Type of Cell Culture, Mode of Operation, End User and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering. The ‘Mini Bioreactors and Micro Bioreactors Market, 2022-2035’ report features an extensive study of the current landscape and the … [Read more…]

The first-of-its-kind, CRISPR-based therapeutic aims to stop the progression of Duchenne muscular dystrophy in a single-patient dosing BOSTON–(BUSINESS WIRE)–Cure Rare Disease (CRD) – a Boston-based 501c3 nonprofit biotech – announces the approval from the U.S. Food and Drug Administration (FDA) to administer its very first therapeutic. The drug, named CRD-TMH-001, treats muscle promoter and exon … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Needlestick Safety Injection Devices Market by Type of Device, Purpose of Device, Usability, Company Size and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering. The “Needlestick Safety Injection Devices Market” report features an extensive study on the current market landscape, offering an informed opinion on … [Read more…]

– Just – Evotec Biologics will apply its fully integrated technology platform to develop an optimized commercial process for ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases – HAMBURG, Germany & SEATTLE–(BUSINESS WIRE)–Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Alpine Immune Sciences, Inc. … [Read more…]

Mr. Nunn will add unparalleled pharmaceutical industry insights for Humanetics, which is advancing its lead drug candidate BIO 300 through clinical trials MINNEAPOLIS–(BUSINESS WIRE)–Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies for COVID-19, has announced the addition of renowned venture capitalist and life science industry … [Read more…]

CHICAGO–(BUSINESS WIRE)–The demands of examinations for independent testing institutes and labs have been expanding and growing from the continuous impact of the pandemic. Taiwan Excellence is leading a team of award-winning medical testing products to attend the largest and most influential global expo, AACC in Chicago, aiming for post-pandemic business opportunities. Many countries have been … [Read more…]

SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with … [Read more…]

— FDA Cleared IND Application for STAR-0215 for the Treatment of Hereditary Angioedema — — Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects Initiated, Preliminary Results Anticipated by Year-End 2022 — — Company to Host a Virtual R&D Day on September 30 — BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for … [Read more…]

Strong second quarter sales of $2.2 billion, up 5%, or 10% constant currency (cc) Second quarter earnings of $0.30 per diluted share, down 3%, or up 34% cc Second quarter core earnings of $0.63 per diluted share, up 13%, or 30% cc Updated 2022 full year outlook reflects strong underlying operational performance, impacted by strength … [Read more…]